Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic

  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Seagen Inc (NQ: SGEN )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 13, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Seagen Inc

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
SEAGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Seagen Inc. - SGEN
From Kahn Swick & Foti, LLC
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Seagen to Highlight Data From Oncology Portfolio and Pipeline at the 2023 American Society of Clinical Oncology Annual Meeting
From Seagen Inc.
Via Business Wire
2 Excellent Dividend Stocks to Buy for Less Than $100
Both companies are steals at current levels. 
Via The Motley Fool
Here's How Much You Would Have Made Owning Seagen Stock In The Last 5 Years
Via Benzinga
Here's How Much You Would Have Made Owning Seagen Stock In The Last 5 Years
Via Benzinga
Analyst Ratings for Seagen
Via Benzinga
Second Quarter Outlook For Biotech Stocks
Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity. 
Via Talk Markets
SGEN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Seagen Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
3 Low P/E Stocks That Will Double in One Year
These are the low-PE stocks to buy and represent companies with strong fundamentals and cash flow potential. 
Via InvestorPlace
Hedge Funds Fall Short: Underperforming Low-Cost S&P 500 ETF By 6% In 2023. Here's Why.
So far, 2023 has not started well for the hedge fund sector, as a common SPDR S&P 500 Trust ETF (ARCA: SPY) fared much better than the Global X Guru Index ETF (ARCA: GURU), a fund that invests in the... 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
This Biotech's Stock Has Been Under Pressure, Could Upcoming Clinical Trials Of Its Nanotechnology-Based COVID Drug Candidate Be The Start Of An Upward March?
A company that seems to have seen poor market sentiment lately is NanoViricides Inc. (NYSEAMERICAN: NNVC), a pharmaceutical company specializing in the development of nanomedicine drugs for treating... 
Via Benzinga
Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis
Tiziana Life Sciences (NASDAQ: TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) at the... 
Via Benzinga
Consider This Undervalued Pharma Giant Before Its Blockbuster Deal Closes
Wall Street isn't showing one of pharma's most prominent players any love. 
Via The Motley Fool
Seagen to Report First Quarter 2023 Financial Results on April 27, 2023
From Seagen Inc.
Via Business Wire
Is Pfizer Stock a Buy, Sell or Hold? Here’s My Call.
Pfizer can't depend on Covid-19 vaccines as a revenue source in 2023, but PFE stock can still grow as the drugmaker broadens its pipeline. 
Via InvestorPlace
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Univar Solutions Inc. (NYSE - UNVR), Oak Street Health (NYSE – OSH), Seagen Inc. (Nasdaq - SGEN), U.S. Xpress Enterprises, Inc. (NYSE – USX)
From Brodsky & Smith LLC
Via GlobeNewswire
FDA Approves Merck's Keytruda Combined With Seagen/Astellas's Padcev For Advanced Urothelial Cancer
Via Benzinga
FDA Grants Accelerated Approval for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer
From Seagen Inc.
Via Business Wire
Up 463%, This Sizzling Growth Stock Could Have a Lot More Room to Run
Viking Therapeutics stock might in the midst of a historic run. 
Via The Motley Fool
It's Not Tesla, Meta Or Nvidia — The Best Performing Large-Cap Stock In 2023 Is A Crypto Play
The SPDR S&P 500 ETF Trust (NYSE: SPY) has seen a positive return in 2023. Several sectors are in the green so far this year, and many well-known stocks are among the biggest gainers. Here’s a look at... 
Via Benzinga
Merck Germany Regains Exclusive Global Rights To Cancer Drug From Pfizer
Via Benzinga
3 Low P/E Stocks That Are Bound to Rebound This Year
These are the low P/E stocks to buy at current levels for a sharp reversal rally in the coming quarters. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For March 24, 2023
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Oak Street Health (NYSE – OSH), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)
From Brodsky & Smith LLC
Via GlobeNewswire
Why Pfizer Likely Isn't Done With M&A After the Seagen Deal
Pfizer's stock remains down despite its latest dealmaking, but it may only be a matter of time before it starts to rally. 
Via The Motley Fool
3 Dividend Contenders to Buy Now for Long-Term Gains Later
Dividend stocks have a role to play in any portfolio, and this article highlights three dividend contenders that you can buy now to get long-term gains later 
Via MarketBeat
Pfizer Has Another Blockbuster on the Horizon, but That's Not All
The drugmaker continues to grab headlines for the right reasons. 
Via The Motley Fool
1 Top Healthcare Stock That Could Make You Richer in the Next Decade
The Pfizer of tomorrow will be larger and even more lucrative to hold than it is now. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.